Downstream Processing Industry News
-
HIV Immunity Study Could Pave Way For Vaccine Development
7/17/2012
Two Los Alamos National Laboratory scientists are among the team recently funded to explore ways to create the precise immune factors needed for effective vaccines against HIV.
- Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% Of Flu Deaths 7/10/2012
-
Sinovac Reports Progress In EV71 Vaccine Phase III Clinical Trial And Commercialization Preparation Status
6/25/2012
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today provided an update on its Phase III clinical trial progress and commercialization preparation for its proprietary inactivated Enterovirus 71 (EV71) vaccine against hand, foot and mouth disease (HFMD).
-
HIV Vaccine Trials Network Opens Enrollment For Phase 1 Trial Of GeoVax Labs' Second Generation HIV Vaccine
5/22/2012
GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that the NIH-funded HIV Vaccine Trials Network (HVTN) has opened enrollment for a Phase 1 trial for the company's second-generation HIV vaccine.
-
Ceregene Parkinson's Disease Study Demonstrates Long-Term Neurturin Expression And Enhanced Dopamine Activity 4 Years Following Delivery Of CERE-120 (AAV2-neurturin)
5/17/2012
Ceregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data demonstrating long-term, biologically-active expression of neurturin, a nervous system growth factor delivered to the degenerating dopamine nerves in patients with Parkinson's disease following treatment with CERE-120 (AAV2-neurturin).
-
Generex Announces New Members Of Antigen Express Scientific Advisory Board For The AE37 Breast Cancer Vaccine
5/17/2012
Generex Biotechnology Corporation (OTCBB: GNBT.OB) is pleased to announce today that new members have joined the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc. for the company's AE37 breast cancer vaccine.
-
Inovio Pharmaceuticals' Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses In Phase I Trial
5/16/2012
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its SynCon® avian influenza vaccine generated protective HAI titers against six different unmatched strains of H5N1 in a phase I clinical trial - a distinct clinical achievement on Inovio's path to develop universal influenza vaccines.
-
Shingles Vaccine Is Safe, According To New Study
4/23/2012
The herpes zoster vaccine, also known as the shingles vaccine, is generally safe and well tolerated according to a Vaccine Safety Datalink study of 193,083 adults published online in the Journal of Internal Medicine.
-
RocheĀ“s MagNA Pure LC 2.0 System For Monitoring DNA In Therapeutic Proteins And Monoclonal Antibody Drugs
3/1/2012
To ensure product safety, clearance of host-cell DNA is essential when manufacturing therapeutic proteins and monoclonal antibody (mAB) drugs.
-
Waters And NIBRT Complete Work On World's First UPLC Glycan Database
1/23/2012
Waters Corporation (WAT:NYSE) and Ireland's National Institute for Bioprocessing Research and Training (NIBRT) announced today the availability of the world's first database for glycan analysis by UltraPerformance Liquid Chromatography® (UPLC®).